all the ones that had good run up have ALL sold out last 2 weeks....even with OVAS, their longwood fund and the deer IV fund has BOTH sold out last 2 weeks. See their holdings now vs. 9/30. Its also on stocktwits.
bios got bit heated too much last couple of months...look at kite etc.
will revisit later.
they already proven it technology and scientifically. Get it into trials at the test locations they have with Augment.
they are launching Augment in the largest IVF network in Japan mid 2015. and Japan is huge % for number of IVFs done in the world.
Stock analysts at Wedbush set a $60.00 price objective on shares of OvaScience (NASDAQ:OVAS) stock in a report issued on Tuesday. The firm currently has a a “buy” rating on the stock. Wedbush’s price target suggests a potential upside of 21.29% from the company’s current price.
In other OvaScience news, Director Thomas Malley purchased 35,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were purchased at an average price of $50.00 per share, with a total value of $1,750,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Several other analysts have also recently commented on the stock. Analysts at Oppenheimer upgraded shares of OvaScience from a “market perform” rating to an “outperform” rating in a research note on Friday, January 2nd. Analysts at Leerink Swann raised their price target on shares of OvaScience from $23.00 to $56.00 and gave the company an “outperform” rating in a research note on Thursday, December 18th. Analysts at HC Wainright raised their price target on shares of OvaScience from $40.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, analysts at Credit Suisse initiated coverage on shares of OvaScience in a research note on Tuesday, December 9th. They set an “outperform” rating and a $60.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $66.20.
It has completed its proof of concept, its pilot and now is going commercial.
How is it that people do not trust any company that does not have FDA approval ? Why is FDA everything ? Lots of drugs approved in EU way before it comes to US FDA approval.
1/13/2015 Thomas Malley Director Buy 35,000 $50.00 $1,750,000.00
On the charts...they just did a 135 million offering...so the stock is absorbing that. That is not selling into strength. Plus underwriters bought 300k shares at $50, instead of waiting 30 days, or not buying. That is bullish. Plus director bought $1.2 million shares at $50.
DO YOUR RESEARCH !!
They just did a presentation at JP morgan health conference..the preso is on their website. Read and you will how what they do. They don't care about US approval..90% of IVFs are outside US. And they have a chart that shows how US has always adopted IVF technologies 1-2 years after it is launched outside. US does not know how to evaluate this kind of technology, so they wait.
So US approval is not a requirement for them.
All their products are NOT under development. Augment is going commercial mid 2015. 2nd one is going end 2015. Their biggest product -ovature...has already shown that EggPCC for human has turned into human egg. This is huge. They are under accelerated development....the science is already proven.
READ THE PRESENTATION DUDE.
CAREFUL INVESTGOR WINS...can you move on to some other stock...you are not providing anything valuable or any insight...just bashing is just dumb.
will see 70 tomorrow.
SSEC overpriced, ADRs cheap.
dude china market is down after going up 60-70%...and ADRs moved down. They are cracking on margin accounts. Nothing to do with China economy. There is no surprise it grew 7.2% in 2014...everyone knows that.
stock is selling off due to this.
In April, OvaScience announced that scientific Co-Founder, David Sinclair, Ph.D., was chosen by TIME as one of the 100 Most Influential People in The World. His research on aging and the key role of mitochondria (the energy source for all cells) contributed to the development of OvaScience’s foundational EggPC technology platform and related applications.
underwriters of their option to purchase an additional 345,000 shares of common stock at the public offering price of $50.00 per share.
This shows confidence by the banks in the stock at $50.
is going to soar in 2015 $100 easy. Commercial launches, Ovature acceleration development.
they know OVAS is going after a market over 20 billion.
From article from Sept 14 -
But OvaScience is also working on two further advances: OvaPrime, for woman that are making too few eggs, and OvaTure, which Tzianabos describes as “the most disruptive technology here,” taking immature egg cells and fertilizing them outside the women’s body, so she doesn’t require hormone therapy at all. If it works, it would disrupt the entire $4 billion hormone business now dominated by players like Roche and Teva.